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ABSTRACT 
Background: Cancer is one of the two leading fatal diseases humans face. Synthesized drugs 
available for cancer intervention have many limitations in applications and effectiveness and 
are  often  associated  with  serious  of  side  effects,  which  can  further  damage  the  patients’ 
quality  of  life.    Recently,  the  development  of  natural-product-based  and  therapeutically 
sound anti-cancer agents have gained popularity in the fields of functional and medical foods, 
which may exhibit advantages of minimal toxicity and multiple active molecular components. 
Citrus peel or its extract has been reported to have potent pharmacological activities and 
health benefits because of abundant flavonoids present in citrus  fruits, particularly in the 
peels.     
 
Results: The  results  of  these studies  demonstrated the  efficacy  of Gold  Lotion  (GL),  an 
extract of multiple varieties of citrus peels that contains abundant flavonoids, including a high 
percentage of polymethoxylflavones (PMFs), which can protect against skin cancer, colon 
cancer,  and  prostate  cancer  in  mice.    These  results  are  clearly  promising  and  warrant  a 
human trial with GL in future studies.     
 
Summary: Briefly, these data have demonstrated that GL is efficacious in preventing and 
treating cancer in several model systems. This review summarizes the results of currently 
available data regarding the in vivo anti-cancer activity of GL, and identifies opportunities for 
subsequent  human  clinical  trials  to  assess  preventive  and  therapeutic  effects  in  the  near 
future. 
 
Keywords: gold lotion, citrus peel extracts, skin cancer, colon cancer, prostate cancer   
 Functional Foods in Health and Disease 2014; 4(3):120- 129                                                 Page 121 of 129 
1. BACKGROUND 
Citrus peel is a rich source of flavonoids and almost the sole source of polymethoxyflavones. 
Traditional use of citrus peel, such as aged tangerine peels, can be traced back to 10 century 
BC. However, the exploration of the biological activity of citrus peel started a decade or so 
ago, and since then, a plethora of its biological functions important to health and diseases 
have  been  identified
1,2.  The  biological  functions  of  citrus  peels  investigated  include 
inflammation inhibition, cancer prevention and intervention, hypolipidemia, and regulation of 
metabolic  syndrome.  In  this  paper,  we  summarize  the  in  vivo  anti-cancer  effect  of  a 
specifically formulated product: Gold Lotion or GL, which is comprised of extracts from the 
peels  of six citrus  fruits  produced in  Japan.  In  the characterization of  the  phytochemical 
composition  of  GL,  we  have  found  abundant  flavonoids  and  a  high  content  of 
polymethoxyflavones,  which  consists  of  a  total  concentration  of  more  than  550  ppm  of 
flavonoids in the formulated liquid form of GL
3. 
 The anti-cancer activity of GL was previously evaluated on three mouse models, namely, 
skin cancer
4, colon cancer
3, and prostate cancer
5.    In a mouse skin cancer model, the topical 
application  of  GL  effectively  inhibited  molecular  markers  of  skin  inflammation  and 
attenuated DMBA/TPA-induced skin tumor formation by reducing the tumor incidence and 
tumor multiplicity of papillomas at 20 weeks. These in vivo data indicate that GL can be an 
effective  anti-tumor  agent  capable  of  preventing  inflammation  associated  skin 
tumorigenesis
4. 
 In the model of AOM (azoxymethane)-induced colonic tumorigenesis, oral feeding of 
GL decreased the number of aberrant crypt foci (ACF), and the proportion of large ACF in 
colonic  tissues  of  mice.  Both  gene  and  protein  expression  of  iNOS  and  COX-2  were 
suppressed by GL treatment. The in vivo data have revealed for the first time that the citrus 
peel extract, GL, is an effective anti-tumor agent mechanistically down-regulating the protein 
levels of iNOS, COX-2, ODC, VEGF, and MMP-9 in colonic tissues of mice, suggesting a 
mechanism underlying its therapeutic function
3. 
 Prostate cancer is one of the most prevalent male diseases
6.    While mortality due to 
prostate cancer has decreased recently owing to improved early diagnosis and selection of 
more efficacious medicinal substances
7, it remains one of the most common malignancies 
with a high incidence, an increase in hormone-resistant types, and metastasis
8. In searching 
for efficacious and low toxicity medications against prostate cancer, we evaluated GL in a 
xenograft  mouse  model.  Our  data  demonstrated  that  treatment  with  GL  by  either 
intraperitoneal  (i.p.)  injection  or  oral  administration  dramatically  reduced  the  weight  and 
volume  of  the  prostate  tumor  without  observed  toxicity.    This  inhibitory  effect  was 
accompanied  by  a  down-regulation  of  proteins  associated  with  inflammation  (iNOS  and 
COX-2), metastasis (MMP-2 and MMP-9), angiogenesis (VEGF) , and induction of apoptosis 
in prostate tumors.    Encouraging results as shown above suggest that GL be an effective 
anti-cancer  agent  and  provide  a  potential  new  therapeutic  option  for  prostate  cancer 
treatment
5.   
 
2. METHODS   
This section is a brief summary of the materials and methods used in each anti-cancer study.   
The  detailed  procedures  including  materials  and  methods  were  described  in  previous 
published research papers as cited herein
3-5. 
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2.1 Experiments in mouse skin cancer
4   
Animal handling. Female ICR mice (5–6 weeks old) were housed in a controlled atmosphere 
(25 ± 1
 oC, 50% relative humidity) with a 12-h light/12-h dark cycle. The dorsal skin of each 
mouse was shaved with surgical clippers before the application of tested compound. GLand 
TPA were dissolved in 200 µL of acetone and applied topically to the shaved area of each 
mouse. 
  
Measurement  of  epidermal  hyperplasia.  The  measurement  of  epidermal  thickness  is 
described in previous paper
4.   
 
Western blot analysis. The mice were treated topically with GL on their shaved backs 30 
min prior to 10 nmol of TPA treatment. The rest of the detailed procedure is illustrated in 
previous paper
4.   
 
Reverse  transcription–polymerase  chain  reaction  (RT-PCR)
4.  Total  RNA  was  isolated 
from scraped colon mucosa and changes in the steady-state concentration of mRNA in iNOS, 
and COX-2 and β-actin were assessed by RT-PCR. Total of 2 µg RNA was transcribed into 
cDNA using SuperScript II Reverse Transcriptase to a final volume of 20 µL. RT reactions 
were performed at 50 
oC for 50 min then 70 
oC for 15 min. The thermal cycle conditions were 
initiated at 95 
oC for 1 min, and 30 cycles of amplification (94 C for 30 s, 58
 C for 25 s, and 
72 C for 1 min), followed by extension at 72 
oC for 3 min. The complementary DNA was 
amplified  by  PCR  with  the  primers  iNOS,  COX-2,  and  -actin,  as  defined  in  previous 
published procedures. PCR products were analyzed by 1% agarose gel and visualized by 
ethidium bromide staining. 
 
Two-stage skin carcinogenesis model
4. Twelve female ICR mice were given commercial 
rodent pellets and fresh tap water ad libitum. The dorsal region of each mouse was shaved 
two days prior to initiation.    Six week old mice were treated with 200 nmol of DMBA in 
200 µL acetone and the control group only received 200 µL of acetone. One week after 
initiation, the mice were topically treated with 200 µL acetone or with TPA (5 nmol in 200 µL 
acetone) twice a week for 20 weeks. For the two GL-treated groups, the mice were applied 
with GL(100 µL) 30 min before each TPA treatment. Tumors of at least 1 mm
2 of diameter in 
an electronic digital caliper were counted and recorded twice weekly, and the diameter of 
skin tumors were measured at the same time.   
 
2.2 Experiments in mouse colon cancer
3   
Six week old male ICR mice were randomly distributed into four groups, and groups 2, 3, 
and 4 were given AOM at a dose of 5 mg/kg via an i.p. injection twice a week for 2 weeks, 
and group 1 was received saline by i.p. injection.    All groups of mice were fed with the daily 
control diets. Groups 3 and 4 were orally administered with 100 and 200 μL of GL five times 
a week, respectively. Groups 1 and 2 were given 200 μL of phosphate-buffered saline (PBS). 
The diet intake of the animals was monitored daily. After 6 weeks of feeding, mice were 
sacrificed by CO2 asphyxiation for evaluation of ACF in colonic tissues. The liver, kidneys, 
and spleen were removed and weighed. The entire colon was excised, cut longitudinally, 
rinsed with PBS, and fixed flat between sheets of filter paper with 10% buffered formalin 
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2.3 Experiments in mouse prostate cancer
5   
In vivo tumor xenograft study. Male Balb/c nude mice of 3-4 weeks old were used in this 
experiment. Prostate cancer PC-3 cells (American Type culture Collection, Manassas, VA, 
3×10
6) in  0.2 mL PBS  were injected subcutaneously between the scapulae of each nude 
mouse. After transplantation, tumor size was measured using calipers, and the tumor volume 
was estimated according to the following formula:    tumor volume (mm
3)=L×W
2/2, where L 
is the length and W the width. Once tumors reached a mean size of 50-100 mm
3, animals 
were  subjected  to  i.p.  treatment  or  oral  administration  of  GL.  In  i.p.  treatment,  animals 
received  i.p.  injections  either  50  µL  of  PBS  or  two  dosages  of  GL,  25  µL  or  50  µL, 
respectively, five times per week for 23 days. Animals were orally administered with either 
200 µL of sterile water or GL (50 µL or 100 µL) five times a week for 21 days. At the end of 
experiment, tumors were excised, weighed, and subjected to western blot analysis. Average 
tumor  volume  and  tumor  weight  ratios  of  each  group  were  measured  at  the  end  of  the 
experiment and represent the mean ± SD. 
 
Western blot analysis. Protein analyses were performed, and the primary antibodies used 
were iNOS, MMP-2, MMP-9, PCNA, and VEGF polyclonal antibodies, as well as COX-2 
and caspase-3 monoclonal antibody.    The detailed protocol and antibody information was 
described in the original research paper
5.   
 
3. RESULTS AND DISCUSSION 
3.1 Inhibition of mouse skin cancer by GL
4 
3.1.1 Inhibition of iNOS and COX-2 expression by GL in mouse skin 
In the TPA-induced acute inflammatory response model in mouse skin,    treatment with TPA 
induced both iNOS and COX-2 expression in mouse skin, as measured by western blot and 
semi-quantitative PCR analysis. In this model, a topical application of 100or 200 µL GL 30 
min prior to  TPA treatment  resulted in  an apparent dose-related reduction of iNOS  gene 
expression,  as  well  as  a  dramatic  reduction  of  TPA-induced  expression  of  these 
inflammation-associated proteins and ODC protein, which has been associated with tumor 
promotion. 
 
3.1.2 GL Inhibition of TPA-induced epidermal hyperplasia in mouse skin 
A  dose  of  10  nmol  TPA  application  led  to  marked  edema  and  an  increase  in  epidermal 
thickness (5.4 ± 1.9 µm in acetone group versus 13.2 ± 0.7 µm in TPA group). However, , 
treatment  with  100  and  200  µL  of  GL  prior  to  TPA  application  significantly  reduced 
epidermal thickness in a dose-dependent manner (10.1 ± 1.3 µm in 100 µL GL group and 8.9 
± 1.4 µm in 200 µL GL group).   
 
3.1.3 Inhibition of tumor promoting effects in two-stage carcinogenesis skin model 
The mouse skin model of multistage carcinogenesis can be divided into three distinct stages: 
initiation,  promotion,  and  progression
9  [8],  which  serves  as  a  major  in  vivo  model  for 
studying  the  sequential  and  stepwise  evolution  of  the  cancer  process  by  chemical  and 
physical carcinogens. The steps of this standard model include topical application of a single 
sub-carcinogenic  dose  of  skin  carcinogen,  such  as  DMBA  that  causes  irreversible  DNA 
damage; then repeated application of promoters, most commonly phorbol esters, such as TPA 
to induce cell proliferation and inflammation
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of initiated epidermal cells and leads to the formation of multiple squamous papillomas.   
In the two-stage skin carcinogenesis model to assess the antitumor-promoting potential 
of GL, the untreated positive control group of mice had 16 ± 3 papillomas per mouse and a 
100%  incidence  of  skin  tumors  at  20  weeks,  whereas  no  tumors  were  observed  in  the 
negative  control  group  following  acetone  application.  However,  when  100  µL  GL  was 
applied  to  the  shaven  backs  of  mice  30  min  prior  to  each  TPA  application,  the  average 
number of papillomas per mouse was 12 ± 4 (25% reduction compared to positive group). In 
addition, the tumor incidence was found to be 100 % in positive group whereas GL-treated 
group showed significantly decreased at 81%. Moreover, the weight of the tumors in the 
positive group was 0.31 ± 0.12 g, but significantly lower in GL-treated group (0.11 ± 0.07 g).   
 
3.1.4 Tumor size decrease and inhibition of angiogenetic molecule expression in mouse 
skin tumors. 
The number of papillomas (≧5 mm in diameter) per mouse was significantly decreased in the 
GL treated group (9 ± 2 in positive group and 6 ± 1 in GL group). In addition, in the positive 
control group in which mouse skin tumors were initiated by DMBA and promoted by TPA for 
20 weeks, the protein expression of ODC, COX-2, and VEGF (vascular endothelial growth 
factor) was apparently increased compared to healthy skin tissue. However, treatment with 
100 µL of GL resulted in a strong reduction of ODC, COX-2, and VEGF protein levels in 
skin  tumors.    ODC  is  involved  in  cancer  proliferation  and  both  COX-2  and  VEGF 
contribute to angiogenesis, hence we suggest that GL reduced tumor size by inhibiting the 
tumor growth and angiogenesis. 
 
3.2 Colon cancer inhibition by GL
3 
In the AOM model, the progression is from ACF (aberrant crypt foci) to adenomas and to 
invasive cancers. During this progression, formation of ACF in the early stage is considered 
to be a histological biomarker of colonic tumor development
11. Large ACF are dysplastic, 
with histological features of micro adenomas that are associated with an increased risk for 
malignant progression
12. In the efficacy study of GL against colon cancer, the number of 
ACFs in GL (200 µL) treated mice is 12 ± 2 (P<0.05), remarkably lower than non-GL-, but 
AOM-treated group of mice (16 ± 2). Surprisingly, the number of larger ACFs was targeted 
first and reduced to 16 ± 3 (100 µL GL) and 15 ± 2 (200 µL GL) respectively, compared to 25 
± 3 ACFs in the AOM-treated positive control group (P<0.05)
3.   
The development of colorectal cancer involves various genetic and molecular changes in 
cell proliferation, inflammation, resistance to apoptosis, angiogenesis, and metastasis
13. Over 
expression of iNOS and COX-2 enzymes contribute to the promotion of tumorigenesis by 
induction of inflammation, abnormal cell proliferation, and decreasing apoptosis
14. Thus, the 
effect of GL on AOM-induced inflammatory (iNOS and COX-2), proliferative (ODC) and 
angiogenic (VEGF and MMP-9) molecule expression in mouse colon, was assessed.    As 
shown in Figure 1A, expression of inflammatory enzymes iNOS and COX-2 were increased 
in AOM-treated group. However, oral administration of GL at dosages of100 µL and 200 µL 
dose-dependently decreased AOM-induced iNOS and COX-2 protein level in mouse colon 
compared with the AOM-treated positive control group.    Also, the gene expression of both 
iNOS  and  COX-2  genes  were  markedly  reduced  in  GL-treated  groups  compared  to 
AOM-treated group (Figure 1B).    Interestingly, the gene expression of COX-2 showed a 
complete decrease in 200 µL of GL treated group (Figure 1B).    These results suggested that Functional Foods in Health and Disease 2014; 4(3):120- 129                                                 Page 125 of 129 
the anti-inflammatory activity of GL might be one of the mechanisms for its chemopreventive 
activity  in  inhibiting  AOM-induced  colonic  tumorigenesis.  In  addition,  the  proliferative 
marker ODC, the metastasis marker MMP-9, and the angiogenic molecule VEGF, which 
were up-regulated in AOM-treated mouse colon, were apparently reduced in a dose-related 
fashion by oral administration of GL. Therefore, the suppression of ACF formation might be 
through GL inhibiting cellular proliferation and angiogenesis in the colonic mucosa 
3.These 
results  suggest  that  the  mechanism  of  in  vivo  chemopreventive  efficacy  of  GL  includes 
anti-inflammation,  anti-proliferation,  and  anti-angiogenesis  in  AOM-induced  colonic 
tumorigenesis. 
 
Figure 1A                    Figure 1B 
 
Figure 1
3. Inhibitory effects of oral administration of GL on AOM-induced protein levels in 
colorectal tissue. (A) Protein lysates from normal colonic mucosa and ACF of each group 
were extracted  and subjected to  Western Blot analysis for iNOS,  COX-2, COX-1, ODC, 
VEGF  and  MMP-9  protein  levels.  -actin  as  an  internal  control.  The  western  blot  is  a 
representative of at least three independent experiments. Quantification of iNOS, COX-2, 
COX-1, ODC, VEGF and MMP- -actin using a 
densitometer. (B) Effect of oral administration of GL on AOM-induced inos and cox-2 gene 
expression in colorectal tissue. RNA from normal colonic mucosa and ACF of each group 
were extracted and subjected to RT-PCR analysis for inos and cox-2 gene expression.   
 
3.3 prostate cancer
5 
The human prostate tumor xenograft model has been widely used in cancer therapy research 
and  anti-cancer  drug  development
15.  To  evaluate  potential  therapeutic  effects  on  prostate 
cancer, GL was tested in immune-deficient mice bearing human prostate cancer cell line PC-3 
tumor xenografts. After the establishment of palpable tumors, animals received i.p. injections 
of 25  An unexpectedly potent inhibition 
of PC-3  xenograft tumor formation  was  observed by i.p.  injection of  GL at  25  µL. The 
prostate xenograft tumor was almost completely eliminated in the group treated with 50 µL of 
GL(Figure 2).   
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Figure 2A 
 
 
Figure 2B                      Figure 2C 
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Figure 2. The growth of PC-3 tumor xenografts in nude mice was reduced by i.p. treatment 
with GL. (A) Whole body imaging of PC-3 tumor-bearing mice from control and GL group. 
(B) Average tumor weight and (C) tumor volume were measure at the end of experiment. 
Five samples were analyzed in each group, and values represent the mean ± SD. 
#P < 0.01 
and 
##P< 0.001, compared with control group.   
 
Consistent  with  this  observation,  both  tumor  weight  and  tumor  size  were  markedly 
decreased in the group treated with  25 µL of GL. Mice in the control group showed an 
average tumor weight of 1.66 ± 0.31 g, whereas this was significantly lower in the group 
treated with 25 µL GL i.p. , at 0.71 ± 0.33 g (P<0.01) (Figure 2B).    Similarly,    the average 
tumor volume was significantl
that of the control group (659.6 ± 211.1 mm
3 vs. 3082.0 ± 680.4 mm
3 respectively; Figure 
1C).    Based on these results, tumor weight and tumor volume were dramatically inhibited by 
i.p. injection of GL in the PC-3 xenograft model
5.     
Therapeutic effects of oral dosing with GL were also evaluated in this model.    Animals 
were treated orally with 50  or  of GL in two groups five times per week for 21 
days. At the end of the study, the body weight in each group was not significantly different Functional Foods in Health and Disease 2014; 4(3):120- 129                                                 Page 127 of 129 
(Figure 3A): positive group: 20.41 ± 2.11 g; 50 L GL group, 21.22 ± 0.53 g; and 100 LGL 
group, 21.34 ± 0.90 g.   
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Control GL-50 (oral) GL-100 (oral)
B
od
y
 w
eigt
 (g
)
0
5
10
15
20
25
     
 
Figure 3C 
Control GL-50 (oral) GL-100 (oral)
Tu
mor
 v
olume (
mm
3
)
0
200
400
600
800
1000
1200
1400
1600
# #
 
Figure 3. Oral administration of GL suppressed the growth of PC-3 tumor xenografts in nude 
mice. (A) Body weight and (B) representative photo images of PC-3 tumor-bearing mice 
from each group at day 21. (C) Tumor volume were measure at the end of experiment. Five 
samples were analyzed in each group, and values represent the mean ± SD. Significantly 
different at 
#P<0.01 compared to control group. 
 
Figure 3B shows the in vivo macrograph of the PC-3 tumor-bearing mice.    After 21 
days, nude mice bearing prostate tumor xenografts were visible in control group (arrow).   
Furthermore, a marked inhibition of PC-3 xenograft tumor number and size was observed by 
oral  GL  treatment.  The  average  tumor  size  in  positive  group  was  1021.9  ±  476.2  mm
3 
whereas in the orally GL treated group, both 50 L and 100 L, dramatically reduced tumor 
size to 57.7 ± 42.0 mm
3 and 69.1 ± 9.9 mm
3, respectively (Figure 3C). No dose-response 
between GL oral feeding of 50 L and100 L group was observed.    These results provided 
evidence that oral administration of GL also exerted anti-prostate cancer activity in vivo.   Functional Foods in Health and Disease 2014; 4(3):120- 129                                                 Page 128 of 129 
Thus we can conclude that GL may serve as a novel chemopreventive and therapeutic agent 
for  prostate  cancer,  regardless  of  administration  method,  either  i.p.  injection  or  oral 
administration
5. 
 
4. CONCLUSION 
In summary, these in vivo studies provide compelling evidence that GL is a potent anti-cancer 
agent  in  cancers  of  skin,  colon,  and  prostate.    The  therapeutic  mechanism  may  include 
inhibition  of  inflammation,  proliferation  and  angiogenesis,  and  induction  of  apoptosis.  A 
characteristic and unusual feature of GL is the high concentration of a diverse assortment of 
PMFs and other flavonoids.    In view of other studies examining the impact of individual 
PMFs and related flavonoids
1, it is possible that the biological properties of GL summarized 
here  are  due  to  an  additive  or  synergistic  interaction  of  the  complex  mixture  of 
phytochemicals,  which  may  provide  enhanced  anti-cancer  efficacy.    The  detailed 
mechanisms by which these PMFs and flavonoids in GL exert optimal benefits remain to be 
further elucidated. However, the evidence presented in this review illustrates that GL could 
prove to be an effective anti-cancer agent, especially against skin, colon, and prostate cancer 
and encourage future research to evaluate its efficacy in human clinical trials. 
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